Clinical Trial

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal expects to complete full submission of the New Drug Application in July 2023CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE)…

1 year ago

Baudax Bio Acquires TeraImmune, Inc.

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the…

1 year ago

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,…

1 year ago

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling…

1 year ago

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune…

1 year ago

Immuron Chairman Transition

MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated…

1 year ago

Samsung Bioepis Releases 2023 Sustainability Report

Highlights key initiatives that will drive the company’s transition towards a more sustainable businessReaffirms commitment to environmentally and socially responsible…

1 year ago

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX),…

1 year ago

BioSenic provides financial update

INSIDE INFORMATION Launch of negotiation with main creditors   Agreement with Global Tech Opportunities (GTO) to secure short term financing Mont-Saint-Guibert,…

1 year ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to…

1 year ago